All News

URI.infection.COrona.jpg

More Bad Safety News for Xeljanz

MedPage Today

Another analysis of the mandatory postmarketing safety study for tofacitinib (Xeljanz) has confirmed what most observers expected: that rates of infection with the drug in rheumatoid arthritis are higher than with tumor necrosis factor (TNF) inhibitors.

Read Article
doctor.study_.decision_0.jpg

JAK Inhibitors in Difficult Still’s Disease

Jack Cush, MD

A small retrospective study suggests that patients with difficult to treat adult-onset Still's disease (AOSD) or sytemic juvenile idiopathic arthritis (sJIA) may respond well to JAK inhibitor (JAKi) agents - presumable by blocking pro-inflammatory cytokines, notably IL-6 and IFN.

Read Article
RheumNow Podcast square

The Great Unknowns (8.5.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, FDA approvals, journal articles from the past week on RheumNow; plus viewer questions. This week great hopes for vitamin D, the great unknows of CSA and the great big mess that is the gout.

Read Article
ACR guidance

ACR Updated Guideline on Vaccinations for Rheumatic Patients

Jack Cush, MD

The ACR has posted a new ACR Clinical Practice Guideline Summary providing recommendations on the use of vaccinations for children and adults with rheumatic and musculoskeletal diseases (RMDs).

Read Article
RA erosions bone ACR

The Approach to Difficult to Treat Rheumatoid Arthritis

Jack Cush, MD

Tan and Buch have reviewed the approach to difficult to treat rheumatoid arthritis (D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options.

Read Article
RheumNow Podcast square

Social Media Questions (7.29.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news, journal reports and rheumatologist cases from the past week on RheumNow.com. This podcast is brought to you by StillsNow.com - be sure to sign up for our monthly StillsNow email and Monthly StillsNow Podcast.

Read Article
Best of

U.S. News & World Report’s 2022–23 Rheumatology Rankings

Jack Cush, MD

The Johns Hopkins Hospital has repeated its top rank among US Rheumatology centers - ranking #1 for the 18th year in a row, according to U.S. News & World Report’s 2022–23 Best Hospitals list released yesterday.

Read Article
figure-1691868_640.jpg

TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted?

Jack Cush, MD

Management of arthralgias before a certified rheumatoid arthritis (RA) diagnosis is challenging - should one use DMARD therapy before clinically evident synovitis in a preemptive effort to avoid or forestall the diagnosis or damage of RA?

Read Article
Study of diet & RA in 100 new RA & 197 controls; fish/seafood consumption assoc w/ less RA risk (OR 0.52; 0.27–0.98); but processed meat intake yielded increased RA risk (OR 3.45; CI 1.78–6.68). No significant association btw RA and red meats or poultry https://t.co/wLpHfA50mY https://t.co/p2EOLBKrwW

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 57 #RA pts. w/ ILD treated with abatacept. Lung progression in 46% before ABA. After median 27 mos of follow-up, ILD - 72% improved or stabilized - 23% worsened - 5% died. No significant change in FVC, DLCO ILD worse assoc w/ DAS28, FVC DLCO https://t.co/kLa61ZS8dt https://t.co/7XhqxcHuCt

Links:

Dr. John Cush RheumNow ( View Tweet)
#RA disease activity drives risk of hospitalized infections (SIE). Study of 3,254 RA pts w/ 529 hospitalized infx. SIE seen 3.8/100 person Yrs in remission, 6.6/100PY w/ low Dz activity & 8/100PY w/ moderate Dz activity. HR was 1.60 w/ LDA and 1.83 w/ MDA https://t.co/i4bSsnRiHk https://t.co/kcN9ZvpSOn

Links:

Dr. John Cush RheumNow ( View Tweet)
521 clinically suspect arthralgia (CSA) pts were assessed - Low educational attainment was associated with increased risk of developing inflammatory arthritis (HR = 2.35), independent of BMI & smoking https://t.co/h1bXDfxaQk https://t.co/g2ign0HDmj

Links:

Dr. John Cush RheumNow ( View Tweet)
The Approach to Difficult to Treat Rheumatoid Arthritis Tan and Buch have reviewed the approach to D2T-RA), with a new EULAR definiation of D2T-RA to foster an approach rationale and concideration of treatment options. https://t.co/CfCvgbl3VP https://t.co/OKzyY79shU

Links:

Dr. John Cush RheumNow ( View Tweet)
Risk of incident & recurrent H.Zoster higher after tofacitinib - Korean claims analysis of 11,720 seropos. RA pts Rx w/ bDMARD or tofacitinib (2011-19). 14% got HZ. Compared to other biologics (ABA), Tofa incr HZ (HR 2.5) & recurrence (HR 3.69) https://t.co/lDuqdtkIjR https://t.co/zJ3ArS3gGs

Links:

Dr. John Cush RheumNow ( View Tweet)
Study of 63 Thalassemia pts (50 transfusion dep) w/ 22% α-, 73% β-, 5% α- & β-thal. 23 had inflammatory rheumatic Dz (IRD: RA 9, gout 6, SLE 3, SpA 2). ANA+ in 10% w/o IRD & Transfusion Dep had more + tests for direct Coombs & ANA https://t.co/QW6ecv98F1 https://t.co/GO3xC86hLc

Links:

Dr. John Cush RheumNow ( View Tweet)
TREAT EARLIER Study - Is MTX Intevention in Pre-Clinical RA Warranted? https://t.co/rGcm1DSwJk https://t.co/paBrJVMXdP

Links:

Dr. John Cush RheumNow ( View Tweet)
No Risk of RA w/ coffee consumption -- Swedish EIRA study, included 2184 early RA pts. High Coffee (>6 cups/day) was assoc w/ increased RA risk (OR 1.50;1.20–1.88) that was lost after adjusting for smoking (OR 1.14;0.89–1.45). https://t.co/3SIeHD4fII https://t.co/NqkjmuzSaV

Links:

Dr. John Cush RheumNow ( View Tweet)
BSRBR mandates LFTs q3 mos if on MTX. 1011 RA pts during the pandemic had median of 5 blood tests & median interval of 57 days. 61% pts had 1 prolonged interval (99-150d) & 24% had multiple. Cytopenia & ^LFTs were not increased by interval length https://t.co/VqY4qIMvOS https://t.co/HcTcmFBuvq

Links:

Dr. John Cush RheumNow ( View Tweet)
210 consecutive #RA pts starting #MTX looked at effect of autoantibodies on drug response. DAS28-CRP low dz activity at 6 mos was significantly lower with SSA+ (56% v 76%, P=0.03) - which was more significant than CCP+ or RF+ https://t.co/DoEtldBXi4 Figures https://t.co/yIECjLiEwl

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you checked out our new sister-site, Still's Now? A new site for Still's disease, autoinflammatory & febrile disorders. https://t.co/oWEugnOB6k https://t.co/5jwiP2Xqrz

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×